Microcap stocks often fly under the radar, and even when they do attract attention, it is usually minimal. Unlike large-cap companies with dozens of analysts dissecting every earnings call, many microcaps have only one or two analysts following them, and sometimes none at all.
That lack of coverage makes microcaps far riskier, since there is little professional research available to separate real opportunities from value traps.
The five companies below each have limited analyst coverage, which means the market has far less information to rely on when pricing them. For investors, that scarcity of research raises the stakes: the upside targets may look exciting, but the risks are amplified by how little scrutiny these stocks actually receive.
In 2025, these five microcaps represent the thin slice of the market where opportunity and danger sit side by side. Their small size and limited coverage make them especially volatile, and investors should recognize that before chasing the eye-catching upside projections.
| Company Name (Ticker) | P/E Ratio | Analyst Upside |
| Myomo (MYO) | -3 | 552% |
| BrainChip (BRN) | -16 | 402% |
| Corbus Pharmaceuticals (CRBP) | -2 | 340% |
| Clear Channel Outdoor (CCO) | 63 | 15% |
| Allakos (ALLK) | -1 | 6% |
Unlock our Free Report: 5 undervalued compounders with upside based on Wall Street’s growth estimates that could deliver market-beating returns (Sign up for TIKR, it’s free) >>>
Myomo (MYO)
Myomo is a medical robotics company that develops wearable devices to assist individuals with neuromuscular disorders in regaining arm and hand function. The company’s recent quarterly revenue grew by 28% year-over-year, signaling strong demand for its MyoPro device.
However, Myomo remains unprofitable, with a deeply negative return on equity, as it continues to invest heavily in research and market development. The stock trades at a very high price-to-sales ratio, reflecting its small revenue base and speculative nature.
Myomo does not pay a dividend, and its financial outlook depends heavily on wider adoption of its technology and successful insurance coverage approvals. Investors may consider Myomo for its exposure to the growing medical device and rehabilitation technology market, especially given the specialized nature of its product and the potential for broader payer reimbursement over time.
Value stocks like Myomo in under a minute with TIKR’s new Valuation Model (It’s free) >>>
BrainChip (BRN)
BrainChip is a semiconductor company specializing in neuromorphic AI processors that mimic brain-like computing for edge applications such as IoT devices and autonomous systems. The company has yet to generate significant commercial revenue, with its sales being highly volatile in recent years.
BrainChip remains unprofitable, posting a deeply negative return on equity of more than -133% due to high R&D expenses and limited operating income. The stock trades at a high valuation relative to its minimal sales and does not pay a dividend.
Despite the risks, investors might find appeal in BrainChip’s early position in neuromorphic computing, especially given the long-term growth of AI hardware and the potential for this technology to carve out a niche in low-power edge computing.
Track BrainChip’s financials, growth trends, and analyst forecasts on TIKR (it’s free)>>>
Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for inflammatory and fibrotic diseases. The company currently has no commercial products on the market and relies on investor capital to fund its clinical trials.
Corbus reported no revenue in its latest quarter and a net loss that resulted in a return on equity of approximately -49% over the past year. The stock does not offer a dividend. The company’s lead drug candidate, CRB-701, is now in Phase 2 clinical testing, with its success being a key factor for the company’s future.
Investors may see Corbus as a speculative biotech pick with binary outcomes, where successful clinical trial results could provide significant upside, though the probability and time frame remain uncertain.
See whether top investors & hedge funds are buying or selling Corbus Pharmaceuticals right now (It’s free) >>>
Wall Street Analysts Are Bullish on These 5 Undervalued Compounders With Market-Beating Potential
TIKR just released a new free report on 5 compounders that appear undervalued, have beaten the market in the past, and could continue to outperform on a 1-5 year timeline based on analysts’ estimates.
Inside, you’ll get a breakdown of 5 high-quality businesses with:
- Strong revenue growth and durable competitive advantages
- Attractive valuations based on forward earnings and expected earnings growth
- Long-term upside potential backed by analyst forecasts and TIKR’s valuation models
These are the kinds of stocks that can deliver massive long-term returns, especially if you catch them while they’re still trading at a discount.
Whether you’re a long-term investor or just looking for great businesses trading below fair value, this report will help you zero in on high-upside opportunities.
Click here to sign up for TIKR and get our full report on 5 undervalued compounders completely free.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
